Event Listing

Teleconference Townhall: Female Condoms of Today and Tomorrow: Strategy Call on R&D Advocacy

Washington, DC / September 30, 2010

Over the years, prevention advocates have learned that no single method is going to be preferred or used by everyone, and that choice is important to users. The same is true of female condoms. Even though the female condom is a relatively young product, there are several female condom models currently available on public or private markets in some countries, the most well-known and widely distributed being the Female Health Company’s U.S. FDA-approved FC2. In addition, entirely new female condoms, such as the Woman’s Condom, are in development and are undergoing clinical trials. But what does it mean when a female condom is in development phases, and how can advocates help get new female condoms into the hands of consumers?

When: Thursday, September 30, 12:00noon – 1:00pm EDT/ 9:00am – 10:00am PDT / 6:00pm – 7:00pm CET

Agenda:

  • Overview of female condoms currently available worldwide - Kimberly Whipkey, Senior Associate for Advocacy and Outreach, CHANGE
  • Female condoms in the research and development pipeline - Patricia Coffey, Senior Program Officer and Woman’s Condom Team Leader, PATH
  • What advocates can do to accelerate female condom research and development - Mitchell Warren, Executive Director, AVAC—Global Advocacy for HIV Prevention
  • Current U.S. and international female condom distribution efforts - Lucie van Mens from Universal Access to Female Condoms (UAFC) Joint Programme; and Jessica Terlikowski, Policy Manager, AIDS Foundation of Chicago
  • Questions and discussion

Co-Sponsored by: Center for Health and Gender Equity (CHANGE), AIDS Foundation of Chicago, AVAC, and PATH.

Link to Kimberly Whipkey's powerpoint

Link to Patricia Coffey's powerpoint

Link to Jessica Terlikowski's powerpoint